Effectiveness of ustekinumab dose escalation in Crohn&apos;s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy

Inflammatory Bowel Disease

Effectiveness of Re-induction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis

Clin Gastroenterol Hepatol

Meserve J, Ma C, Dulai PS, Jairath V, Singh S

doi: 10.1016/j.cgh.2021.10.002

Inflammatory Bowel Disease

Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study

Lancet Gastroenterol Hepatol.

Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G

doi: 10.1016/S2468-1253(20)30188-6.

Inflammatory Bowel Disease

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

Lancet Gastroenterol Hepatol.

Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group

doi: 10.1016/S2468-1253(19)30012-3.

Inflammatory Bowel Disease

Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy

J Crohns Colitis.

Messadeg L, Hordonneau C, Bouguen G, Goutorbe F, Reimund JM, Goutte M, Boucher AL, Scanzi J, Reymond M, Allimant C, Dapoigny M, Pereira B, Bommelaer G, Buisson A

doi: 10.1093/ecco-jcc/jjaa098.

Inflammatory Bowel Disease

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients with Crohn's Disease

Gastroenterology.

Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer S, Feagan BG, Ghosh S, Sandborn WJ

doi: 10.1053/

Inflammatory Bowel Disease

Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC

Clin Gastroenterol Hepatol.

Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ

doi: 10.1016/j.cgh.2019.11.059.

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

Lancet Gastroenterol Hepatol.

Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO

doi: 10.1016/S2468-1253

Inflammatory Bowel Disease

Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort Minimally Invasive Gastrointestinal Surgery

Inflamm Bowel Dis.

Weaver KN, Gregory M, Syal G, Hoversten P, Hicks SB, Patel D, Christophi G, Beniwal-Patel P, Isaacs KL, Raffals L, Deepak P, Herfarth HH, Barnes EL

doi: 10.1093/ibd/izy302.

Inflammatory Bowel Disease

Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy

Inflamm Bowel Dis

Bermejo F, Jiménez L, Algaba A, Vela M, Bastida G, Merino O, López-García A, Melcarne L, Rodríguez-Lago I, de la Maza S, Bouhmidi A, Barreiro-de Acosta M, López-Serrano P, Carrillo-Palau M, Mesonero F, Bonillo D, Granja A, Guerra I

doi: 10.1093/ibd/izab015

Related content

Effectiveness of Re-induction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis

Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients with Crohn's Disease

Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort Minimally Invasive Gastrointestinal Surgery

Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy